Physician profile
Joseph Colucci
NPI 1770506164
$4,023.03
in general payments reported to CMS, 2019-2025
26 companies · $346 in 2025
The $346 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $676 · 2021: $357 · 2022: $606 · 2023: $584 · 2024: $687 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,617.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $719.82 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $544.61 | 2020-2025 | Verquvo, Steglatro, Gardasil |
| Amgen INC. | $395.30 | 2019-2024 | Prolia, Evenity, Repatha |
| Janssen Pharmaceuticals, INC | $301.28 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $256.57 | 2020-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $244.91 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $234.93 | 2019-2025 | |
| Novo Nordisk INC | $199.38 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Daiichi Sankyo INC. | $196.36 | 2021-2024 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $173.18 | 2020-2023 | Fasenra |
| Lilly USA, LLC | $143.29 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $84.37 | 2020-2021 | |
| Boston Scientific Corporation | $71.49 | 2024-2025 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $61.65 | 2021-2022 | |
| Exact Sciences Corporation | $60.41 | 2023-2024 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $54.86 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $53.03 | 2023-2024 | Inpefa |
| Pfizer INC. | $40.69 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $39.26 | 2021-2023 | Livalo |
| Kestra Medical Technology Services, INC. | $32.33 | 2024 | Assure Wcd |
| United Therapeutics Corporation | $29.20 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.74 | 2025 | Jardiance |
| Sumitomo Pharma America, INC. | $19.64 | 2025 | Gemtesa |
| Inspire Medical Systems, INC. | $16.79 | 2023 | Inspire |
| Allergan, INC. | $14.55 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.39 | 2025 | Glassia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Colucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.